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jects, there was no impact of OC exposure on paracetamol 
clearance. Multiple regression revealed a linear association 
(R adj = 0.41, p < 0.001) between paracetamol clearance and 
weight (p = 0.0462) and estradiol (p < 0.0001).  Conclusion: 
Estradiol and weight in part explain the variation in 
paracetamol clearance in young women.  
 © 2014 S. Karger AG, Basel 
 Introduction 
 Paracetamol (acetaminophen) is the most commonly 
used analgesic and antipyretic drug, and is the first choice 
compound for the symptomatic treatment of pain or fe-
ver. In healthy adults, paracetamol is almost exclusively 
eliminated by conjugation into either paracetamol gluc-
uronide (47–62%) or paracetamol sulphate (25–36%), 
while limited amounts (1–4%) are excreted in the urine 
as unchanged paracetamol or undergo oxidation (<10%) 
to result in toxic metabolites (N-acetyl-p-benzoquinone) 
 [1] . Due to its safety profile, paracetamol is commonly 
used during pregnancy, after caesarean delivery or in 
postpartum. However, physiological changes during 
pregnancy (e.g. increased plasma volume and body 
weight, increased metabolic rate and enhanced renal drug 
transport processes) and their subsequent normalisation 
in postpartum influence paracetamol disposition and 
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 Abstract 
 Aim: Paracetamol clearance differs between pregnant and 
non-pregnant women and between women with or without 
specific oral contraceptives (OCs). However, an association 
between female sex hormones and paracetamol clearance 
has never been explored.  Methods: In total, 49 women at 
delivery, 8 female control subjects without OC use, historical 
data of 14 women taking OCs, and 15 postpartum observa-
tions with and without OCs were pooled to explore covari-
ates of paracetamol clearance. All received a single intrave-
nous 2-gram paracetamol dose, and blood samples were 
collected up to 6 h after dosing. High-performance liquid 
chromatography was used to quantify paracetamol. The 
area under the curve to time infinity (AUC 0– ∞ ) was deter-
mined and clearance (l/h   ·   m 2 ) was calculated by dose/
AUC 0– ∞ . In addition, estradiol and progesterone were quan-
tified by ELISA with electro-chemiluminescence.  Results: 
Median paracetamol clearance at delivery was significantly 
higher when compared to postpartum or non-pregnant 
women (11.9 vs. 6.42 and 8.4 l/h  ·  m 2 , at least p < 0.05), while 
an association between paracetamol clearance and estradiol 
was observed (R = 0.494, p < 0.0001). In non-pregnant sub-
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metabolism  [2] . These peripartum alterations may relate 
to changes in female sex hormones. 
 The claim on the link between female sex hormones and 
drug metabolism is supported by in vivo and in vitro stud-
ies in rodents and humans. Rat studies performed in the 
early 70s revealed influences of sex hormones on drug en-
zyme activities  [3] . Transgenic UDP glucuronosyltransfer-
ase (UGT) 1 mice described the influence of circulating 
hormonal factors on UGT 1A gene expression, which is 
involved in paracetamol glucuronidation  [4] . More recent-
ly, Chen et al.  [5] demonstrated that estradiol upregulates 
UGT 1A4 expression in vitro by documenting increased 
lamotrigine glucuronidation in a transfected liver cell 
model. This is in line with in vivo observations in humans, 
since compound-specific studies (e.g. lamotrigine, propo-
fol and paracetamol, all undergoing glucuronidation) show 
raised metabolic drug clearance during pregnancy  [6–8] . 
 Based on these in vivo  observations on compounds pri-
marily eliminated via glucuronidation  [9–11] , and on the 
earlier mentioned in vitro observations  [3–5] , it seems rea-
sonable that estradiol-induced enhanced glucuronidation 
in part explains the increased paracetamol clearance dur-
ing pregnancy. Moreover, oral contraceptive (OC) steroids 
also cause an increased drug metabolism of lamotrigine, 
via induction of the glucuronosyltransferase  [12] , as well 
as a rise in metabolic clearance of paracetamol via induced 
glucuronidation and oxidative pathways  [13, 14] . Conse-
quently, we aimed to explore covariates – including female 
sex hormones – of paracetamol clearance in a further ex-
tended cohort of women undergoing elective caesarean de-
livery compared to postpartum women (intra-individual) 
or those exposed or not to OCs (inter-individual)  [14, 15] .
 Materials and Methods 
 Ethics and Recruitment 
 The study protocol was reviewed and approved by the Ethics 
Committee of University Hospitals Leuven, Belgium (S52366,
EUDRACT 2010-020164-37). A total of 49 women scheduled for 
caesarean delivery were included after written informed consent 
was obtained; 8 of these women initially included at delivery re-
turned for a 2nd paracetamol pharmacokinetic study (n = 8), using 
the same loading dose at 10–15 weeks postpartum, and for a 3rd 
visit (n = 7) approximately 1 year after delivery. We hereby aimed 
to quantify intra-individual pharmacokinetic changes in 
paracetamol clearance at delivery and in early and late postpartum. 
Finally, 8 non-pregnant female control subjects between the ages 
of 27 and 37 years, not taking OCs, were enrolled ( table 1 ). 
 Supplementary Data 
 In addition, raw data from another 14 non-pregnant control 
subjects between the ages of 19 and 32 years, all on OCs, were avail-
able. These data were reported by Gregoire et al.  [16] , indepen-
dently from our data. We hereby aimed to quantify inter-individ-
ual pharmacokinetic differences between women at delivery and 
non-pregnant women, either exposed or not to OCs. 
 Dosing, Sampling, Assay and Female Hormones  
 Blood samples from 49 patients at delivery were collected in 4.5-
ml lithium heparin tubes, through a peripherally inserted venous 
catheter, according to the following schedule: 1, 2, 4 and 6 h after 
intravenous administration of a 2-gram paracetamol loading dose 
over 15 min. Observations in 5/49 patients at delivery had to be ex-
cluded from this analysis since the number of blood samples (n <3) 
available for individual pharmacokinetic calculations was insuffi-
cient. After each sample collection, the peripherally inserted ve-
nous catheter dedicated for blood sampling only was flushed with 
heparin (2 U/ml) to prevent blood clotting and obstruction of the 
catheter. Immediately following collection, blood samples were 
centrifuged at 2,500 rpm for 10 min. Subsequently, plasma was 
transferred to 3.6-ml polypropylene cryotubes (Nunc CryoTubes ® ),
labelled and stored at –20   °   C until high-performance liquid chro-
matography analysis was performed, as described earlier  [17] .
 A subgroup of 8/44 women initially recruited at delivery re-
ceived a second 2-gram paracetamol loading dose during a 2nd 
visit, 10–15 weeks postpartum, of whom 7/8 came back after ap-
proximately 1 year for a 3rd visit, following the same procedure: 
i.e. blood samples were collected at 1, 2, 4 and 6 h after initiation 
of a 2-gram paracetamol loading dose, and handled as described 
before. In addition, 8 female controls using no OCs were also en-
rolled, to whom a 2-gram paracetamol loading dose was adminis-
tered, and blood samples were collected, handled and stored as 
described for postpartum women. Finally, and as mentioned ear-
lier, raw data of similar observations (a single 2-gram intravenous 
paracetamol loading dose, with observations at 1, 2, 4 and 6 h) in 
14 healthy female volunteers were provided by Gregoire et al.  [16] .
 Estradiol and progesterone levels were determined for each (re-
current) patient (44 patients at delivery, 8 cases at 15 weeks and 7 
cases at approx. 1 year postpartum, as well as 8 female controls with 
no OCs) via ELISA with electro-chemiluminescence (MODU-
LAR ® ANALYTICS E-170; Roche/Hitachi) by the clinical labora-
tory of University Hospitals Leuven. Estradiol and progesterone 
observations in the cohort of Gregoire et al.  [16] were not available, 
but all these women were on OCs.
 Pharmacokinetics and Statistics 
 A non-compartmental approach was used to calculate the 
paracetamol pharmacokinetic estimates. After determining the 
paracetamol plasma concentration, the elimination rate constant 
(k e ) was calculated for every individual data set. Subsequently, ter-
minal elimination half-life was derived and the area under the 
curve to time infinity (AUC 0– ∞ ) was determined, as published ear-
lier  [18] . The total plasma clearance (CL) was calculated by dose/
AUC 0– ∞ and the volume of distribution by CL/k e . Paracetamol 
clearance (l/h     ·     m 2 ) was corrected for body surface area (BSA), a 
suitable surrogate for body dimensions. The BSA was calculated 
making use of the Haycock formula (BSA = 0.024265 × weight 0.5378 
× height 0.3964 ), previously used  [18] , and was also applied on the 
data set of Gregoire et al.  [16] .
 Clinical characteristics and individual pharmacokinetic esti-
mates were reported by median and range. Inter-individual data 
were compared using Kruskal-Wallis analysis, while Friedman and 
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Mann-Whitney U analysis were used to analyse intra-individual 
observations. Pearson’s correlation coefficient was determined as 
a measure of statistical dependence between two parameters. Sim-
ple linear regression and Mann-Whitney U analysis were used pri-
or to generating a statistical generalized linear model. Finally, a 
multiple regression analysis was performed, making use of Statis-
tica ® 8, to determine the association between paracetamol clear-
ance and female sex hormones. Statistical analysis and graphical 
representation (mean ± SEM) were performed using MedCalc ® 
12.5 and Prism ® 5.01, respectively. Clinical characteristics were 
tabulated per patient group, with median and range. 
 Results 
 Paracetamol concentrations in 325 samples were avail-
able to calculate 81 paracetamol pharmacokinetic pro-
files. Clinical characteristics, estradiol (pg/ml) and pro-
gesterone (ng/ml) levels, and pharmacokinetic estimates 
in the different cohorts are provided in  table 1 . 
 Effect of Pregnancy and OC Use on Paracetamol 
Clearance 
 Inter-individual differences in paracetamol clearance 
among pregnant women and healthy female controls, ei-
ther OC exposed or not  [16] , are shown in  figure 1 and 
 table  1 . Even after correction for BSA, a significantly 
higher median paracetamol clearance was observed in 
pregnant women (11.9 l/h     ·     m 2 ) compared to healthy fe-
male controls without OCs (8.4 l/h    ·    m 2 , p < 0.05), as well 
as to the historical data set published by Gregoire et al. 
 [16] (9.9 l/h      ·       m 2 , p < 0.01). An effect of OC use on 
paracetamol clearance in non-pregnant women could not 
be established.
 Intra-individual differences in paracetamol clearance 
at delivery and at 15 weeks and approximately 1 year post-
partum are illustrated in  figure 2 . There was a significant 
higher median paracetamol clearance in women at deliv-
ery (11.8 l/h    ·    m 2 ) compared to women 10–15 weeks (6.42 
l/h       ·       m 2 ) and approximately 1 year postpartum (7.13 
l/h    ·    m 2 , both p < 0.05). A difference in paracetamol clear-
ance between both postpartum measurements (15 weeks 
vs. 1 year postpartum) or between women exposed or not 
exposed to OCs in postpartum could not be observed.
 Effect of Gestational Age on Paracetamol Clearance 
during Pregnancy 
 Differences in paracetamol clearance in women deliv-
ering at term ( ≥ 37 weeks, n = 18) or preterm (<37 weeks, 
Table 1. Clinical characteristics, estradiol and progesterone levels, and pharmacokinetic estimates in the different cohorts
Women at delivery Early postpartum Late postpartum Female control
subjects
Data set of Gregoire 
et al. [16]
Number of profiles 49 (44 for analysis) 8 7 8 14
Status at delivery 15 weeks
postpartum
±1 year
postpartum
non-pregnant 
women
non-pregnant 
women
Length, cm 168.0 (150.0 – 182.0) 167.5 (154.0 – 177.0) 162.0 (154.0 – 177.0) 166.3 (162.0 – 174.3) 165.0 (160.0 – 174.0)
Weight, kg 78.0 (57.0 – 110.0) 69.0 (52.2 – 88.0) 62.0 (50.2 – 87.0) 67.2 (54.6 – 74.0) 55.5 (49.2 – 76.0)
BSA, m2 1.95 (1.58 – 2.35) 1.83 (1.51 – 2.01) 1.73 (1.48 – 1.99) 1.78 (1.58 – 1.86) 1.59 (1.49 – 1.89)
OC use not applicable 4/8 2/7 0/8 14/14
Sex hormones 
determined, n 44 8 7 8 0
Estradiol, pg/ml 4,210 (350 – 19,245) 75 (55 – 160) 50 (25 – 216) 53 (29 – 257) not available
Progesterone, ng/ml 83.0 (14.0 – 412.0) 1.0 (0.5 – 2.0) 0.4 (0.2 – 0.7) 0.7 (0.4 – 10.6) not available
Clearance, l/h · m2 11.9 (7.1 – 31.9) 6.42 (5.36 – 7.82) 7.13 (4.97 – 13.25) 8.4 (6.2 – 14.1) 9.9 (6.0 – 13.7)
Distribution volume, l 64.6 (42.0 – 176.2) 35.76 (30.1 – 58.99) 46.94 (36.86 – 65.98) 47.2 (35.8 – 56.0) 46.7 (38.8 – 59.5)
Distribution volume, l/kg 0.77 (0.56 – 2.22) 0.59 (0.35 – 0.84) 0.75 (0.6 – 1.05) 0.76 (0.59 – 0.81) 0.78 (0.67 – 0.92)
Elimination half-life, h 1.82 (1.23 – 4.14) 2.34 (1.36 – 3.58) 2.61 (1.73 – 4.73) 2.26 (1.47 – 2.88) 1.91 (1.56 – 3.11)
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n = 26) were not documented (p = 0.452). Similarly, 
Spearman’s correlation revealed no significant correla-
tion between gestational age and paracetamol clearance 
(R = –0.179, p = 0.244;  fig. 3 ).
 Effect of Female Sex Hormones on Paracetamol 
Clearance 
 As paracetamol clearance was significantly higher in 
pregnant women compared to non-pregnant and post-
partum women (see above), as well as estradiol and pro-
gesterone levels, a correlation analysis was performed to 
quantify the degree to which paracetamol clearance re-
lates to both estradiol and progesterone concentrations. 
Spearman’s analysis revealed a correlation between 
paracetamol clearance and estradiol (R = 0.494, p < 
0.0001), as well as between paracetamol clearance and 
progesterone (R = 0.474, p = 0.0001).
 Generalized Linear Model 
 Based on significant values in simple linear regression 
and Mann-Whitney U analysis, body weight, BSA, and 
estradiol and progesterone concentrations were used in a 
generalized linear model to examine the relationship be-
tween these independent variables and paracetamol clear-
ance. Multiple linear regression revealed a linear associa-
tion (p < 0.001) between paracetamol clearance and the 
independent variables body weight (p = 0.0462) and es-
tradiol levels (p < 0.0001), as shown in  figure 4 . Clearance 
(l/h     ·     m 2 ) = 0.8609 + 0.1248     ·     x + 0.0003     ·     y, R 2 adj = 0.41, 
where x = body weight (kg) and y = estradiol (pg/ml).
15
10
5
0
Women at
delivery
Female control
(–) OC
Gregoire et al.
(+) OC
Cl
ea
ra
nc
e 
(l/
h·
m
2 )
**
*
 Fig. 1. Inter-individual comparison of paracetamol clearance in 
pregnant vs. non-pregnant women. Bar graph provides mean ± 
SEM of paracetamol clearance in women at delivery (n = 44), fe-
male control subjects not taking OCs (n = 8) and non-pregnant 
women with OC use (n = 14, historical data from Gregoire et al. 
 [16] ).  * p < 0.05;  * * p < 0.01. 
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Delivery 15 weeks
postpartum
±1 year
postpartum
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*
*
 Fig. 2. Intra-individual changes of paracetamol clearance in wom-
en at delivery or in postpartum. Bar graph provides mean ± SEM 
of paracetamol clearance in women at delivery (n = 8) and women 
15 weeks (n = 8) and ±1 year postpartum (n = 7), both with and 
without OC use.  * p < 0.05. 
40
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 Fig. 3. Spearman’s correlation between gestational age and 
paracetamol clearance. 
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 Discussion 
 In addition to a weight-related association, the current 
pooled analysis documented a significant positive asso-
ciation between paracetamol clearance (l/h     ·     m 2 ) and es-
tradiol levels, indicating a higher paracetamol clearance 
with increasing estradiol levels ( fig. 4 ). These results were 
obtained by making use of inter- and intra-individual ob-
servations in pregnant women, female control subjects 
(with or without OC use) and women 15 weeks and ap-
proximately 1 year postpartum. 
 The significant correlation between paracetamol clear-
ance and estradiol was to a certain extent expected. This 
is because pharmacokinetic studies of lamotrigine, pro-
pofol and benzodiazepines all showed increased gluc-
uronidation-related clearance of these compounds in 
women during pregnancy and following caesarean deliv-
ery  [6, 8, 19, 20] . Similarly to these drugs, the main route 
of paracetamol elimination is also through glucuronida-
tion. It is likely that the current data are of relevance as an 
illustration of estradiol and weight-driven drug clearance 
in young women, but are also important for the clinical 
pharmacology of paracetamol itself. 
 The possible link between estradiol and glucuronida-
tion is of relevance to improve prediction of drug disposi-
tion in pregnancy for any drug that undergoes glucuroni-
dation such as lamotrigine, propofol, benzodiazepines or 
paracetamol. Wegner et al.  [21] showed that lamotrigine 
plasma levels are reduced by >50% during OC use with an 
increase in lamotrigine levels during the pill-free week, 
with maximum levels 54% higher than baseline (range 29–
129%). Lamotrigine is primarily eliminated via glucuroni-
dation  [22] . In this context, Chen et al.  [5] already present-
ed a potential mechanism contributing to the enhanced 
elimination of lamotrigine during pregnancy, probably 
mediated by both the oestrogen receptor α and the specific-
ity protein-1 binding site, making use of estradiol receptor 
α-transfected HepG2 cells. Buchanan et al.  [23]  suggested 
that female sex hormones are a major contributing factor 
in the glucuronidation-related increase in propofol clear-
ance. Stoehr et al.  [20] suggested an accelerated metabo-
lism of conjugated benzodiazepines, such as temazepam 
and lorazepam, in women taking low-dose oestrogen OCs. 
Finally, Miners et al.  [13] investigated the effect of OC use 
on the individual metabolic pathways for paracetamol, and 
revealed an enhanced glucuronidation in women using 
OCs compared to female control subjects. In essence, our 
study confirms the link between estradiol and phenotypic 
glucuronidation activity, but to a further extent, in a pooled 
study based on 81 pharmacokinetic profiles, collected dur-
ing pregnancy, in postpartum and in healthy female volun-
teers (exposed or not to OCs) and following intravenous 
administration, avoiding absorption-related interferences.
 Besides improved prediction of glucuronidation activ-
ity throughout pregnancy and in postpartum, there are 
also some paracetamol-specific consequences. As a strong 
link between paracetamol concentration and analgesia is 
suggested  [24] , the higher paracetamol clearance in wom-
en during pregnancy results in lower paracetamol plasma 
levels. As a result, less analgesia should be anticipated 
when conventional doses are administered. Physicians 
should be aware that the analgesic effect of paracetamol 
will be shorter in pregnant women or in any setting of 
raised estradiol levels. However, before higher paraceta-
mol doses are considered to compensate for this, we would 
like to refer to the recently published evidence that the 
higher paracetamol clearance during pregnancy is due to 
a disproportional increase in glucuronidation clearance 
and a proportional increase in clearance of unchanged 
paracetamol and in oxidation clearance  [7] . It is likely that 
the latter limits further dose increase in this patient group.
 In line with other recent publications in this journal 
on, for example, the comparison of droperidol, metoclo-
Co
lo
r v
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va
ila
bl
e 
on
lin
e
 Fig. 4. 3D surface plot of paracetamol clearance against plasma es-
tradiol concentration and body weight. Clearance (l/h       ·       m 2 ) = 
0.8609 + 0.1248    ·    x + 0.0003    ·    y, where x = body weight (kg) and y = 
estradiol (pg/ml). 
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pramide, tropisetron or ondansetron to prevent postop-
erative nausea and vomiting following gynaecological op-
erations or chemotherapy during pregnancy  [25, 26] , we 
hereby re-illustrate the need to further explore popula-
tion-specific pharmacokinetics and dynamics of com-
monly used drugs in young women and during pregnancy, 
 In conclusion, weight and estradiol predict to a certain 
extent the variation in paracetamol clearance. The estra-
diol link probably relates to raised glucuronidation activ-
ity and may be of relevance for any drug that undergoes 
glucuronidation. Because of the higher clearance, the an-
algesic effect will be shorter in a setting of higher estra-
diol levels. 
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